Our preclinical evidence of RSM932A and MN58B in TRAF3-deficient mouse B lymphoma and human MM models provides a rational basis for future clinical implementation of CHKα inhibitors or genetic targeting of CHKα as treatments for B cell malignancies. The gene discussed is TRAF3; the disease is Miyoshi myopathy.